OMB Program Assessment Tool Benefits Medical Device Review Reduction
This article was originally published in The Gray Sheet
Executive Summary
FDA's revised target for medical device review times would yield a nearly 10% reduction in total FDA days for half the premarket applications approved between fiscal 2005 and 2007
You may also be interested in...
Peripheral DES Presents Copious Early-Stage Reg Requirements – CDRH Staff
FDA is warning peripheral drug-eluting stent manufacturers not to underestimate the utility of collaborating with the agency early in the preclinical process
Peripheral DES Presents Copious Early-Stage Reg Requirements – CDRH Staff
FDA is warning peripheral drug-eluting stent manufacturers not to underestimate the utility of collaborating with the agency early in the preclinical process
PMA Slowdown To Persist In ’04, McClellan Says; User Fee Hikes To Follow?
FDA expects the rate of new product applications to continue declining for the foreseeable future, despite a series of review cycle improvement initiatives begun in January